Bristol-Myers Squibb Company and Celgene Corporation, In the Matter of

Last Updated:
Case Status:
Pending
In the Matter of Bristol-Myers Squibb Company, a corporation; and Celgene Corporation, a corporation.
FTC Matter/File Number:

191-0061

Docket Number:

C-4690

Enforcement Type:

Part 2 Consents

Case Summary

Pharmaceutical and biologic manufacturers Bristol-Myers Squibb Company and Celgene Corporation have agreed to divest Celgene’s Otezla, the most popular oral treatment in the United States for moderate-to-severe psoriasis, for $13.4 billion. The divestiture settles Federal Trade Commission charges that BMS’s proposed $74 billion acquisition of Celgene would violate federal antitrust law. Under the terms of the proposed consent order, the parties will divest Celgene’s worldwide Otezla business – including its regulatory approvals, intellectual property, contracts, and inventory – to Amgen, Inc. no later than 10 days after consummating the proposed acquisition.